|
Relevé des maladies transmissibles
au Canada
Volume 28 • DCC-2
le 15 janvier 2002
Une déclaration d’un comité consultatif
(DCC)
Comité consultatif national de l’immunisation (CCNI)*†
DÉCLARATION SUR L’UTILISATION RECOMMANDÉE
DU VACCIN CONJUGUÉ CONTRE LE PNEUMOCOQUE
[Précédente]
Références
1. Kertesz DA, Di Fabio JL, Cunto Brandileone MC et coll. Invasive Streptococcus
pneumoniae infection in Latin American children: results of the Pan American
Health Organization Surveillance Study. Clin Infect Dis 1998;26:1355-61.
2. Jetté LP. Laboratoire de santé publique du Québec.
Programme de surveillance du pneumocoque – rapport annuel 1999. URL :
<http://www.lspq.org/vig/pneu99.htm>. Date d’accès : sept. 2001.
3. Chawla R, Kellner JD, Semeniuk H et coll. Population-based surveillance
of Streptococcus pneumoniae infections in Calgary, Canada: influence
of patient age and source of isolate on antibiotic susceptibility. Dans :
Proceedings of the 40th Interscience Conference on Antimicrobial Agents and
Chemotherapy. Toronto (Ontario) : American Society for Microbiology, 2000
: Présentation 1807.
4. Green K, Landry L, Goldenberg E et coll. Effectiveness of a pneumococcal
vaccination program in preventing invasive pneumococcal disease. Dans
: Programs and Abstracts of the 39th Interscience Conference on Antimicrobial
Agents and Chemotherapy. San Francisco (Californie) : American Society
for Microbiology, 1999 : Abstrait no 633.
5. Bjornson G, Scheifele D, Binder F et coll. Taux d’incidence des infections
invasives à pneumocoques chez les enfants : Vancouver, 1994-1998.
RMTC 2000;26:149-51.
6. Scheifele D, Halperin S, Pelletier L et coll. Invasive pneumococcal
infections in Canadian children, 1991-1998: implications for new vaccination
strategies. Canadian Paediatric Society/Laboratory Centre for Disease Control
Immunization Monitoring Program, Active (IMPACT). Clin Infect Dis 2000;31:58-64.
7. Eskola J, Takala AK, Kela E et coll. Epidemiology of invasive pneumococcal
infections in children in Finland. JAMA 1992;268:3323-27.
8. Ekdahl K, Martensson A, Kamme C. Bacteraemic pneumococcal infections
in Southern Sweden 1981-96: trends in incidence, mortality, age-distribution,
serogroups and penicillin-resistance. Scand J Infect Dis 1998;30:257-62.
9. Laurichesse H, Grimaud O, Waight P et coll. Pneumococcal bacteraemia
and meningitis in England and Wales, 1993 to 1995. Commun Dis Public Health
1998;1:22-7.
10. Zangwill KM, Vadheim CM, Vannier AM et coll. Epidemiology of invasive
pneumococcal disease in southern California: implications for the design and
conduct of a pneumococcal conjugate vaccine efficacy trial. J Infect Dis
1996;174:752-59.
11. CDC. Active Bacterial Core Surveillance Report/Emerging Infections
Program Network: Streptococcus pneumoniae, 2001. URL : <http://www.cdc.gov/ncidod/dbmd/abcs/survreports.htm.>.
Date d’accès : sept. 2001.
12. Preventing pneumococcal disease among infants and young children.
Recommendations of the Advisory Committee on Immunization Practices (ACIP).
MMWR 2000;49:1-35.
13. Schuchat A, Robinson K, Wenger JD et coll. Bacterial meningitis in
the United States in 1995. Active Surveillance Team. N Engl J Med 1997;337:970-76.
14. Fleisher GR, Rosenberg N, Vinci R et coll. Intramuscular versus oral
antibiotic therapy for the prevention of meningitis and other bacterial sequelae
in young, febrile children at risk for occult bacteremia. J Pediatr 1994;124:504-12.
15. Jokinen C, Heiskanen L, Juvonen H et coll. Incidence of community-acquired
pneumonia in the population of four municipalities in eastern Finland.
Am J Epidemiol 1993;137:977-88.
16. McIntyre PB, Berkey CS, King SM et coll. Dexamethasone as adjunctive
therapy in bacterial meningitis. A meta-analysis of randomized clinical trials
since 1988. JAMA 1997;278:925-31.
17. Pomeroy SL, Holmes SJ, Dodge PR et coll. Seizures and other neurologic
sequelae of bacterial meningitis in children. N Engl J Med 1990;323:1651-5
18. Kallio MJ, Kilpi T, Anttila M et coll. The effect of a recent previous
visit to a physician on outcome after childhood bacterial meningitis.
JAMA 1994;272:787-91.
19. Turner RB, Lande AE, Chase P et coll. Pneumonia in pediatric outpatients:
cause and clinical manifestations. J Pediatr 1987;111:194-200.
20. Heiskanen-Kosma T, Korppi M, Jokinen C et coll. Etiology of childhood
pneumonia: serologic results of a prospective, population-based study.
Pediatr Infect Dis J 1998;17:986-91.
21. Dowell SF, Butler JC, Giebink GS et coll. Acute otitis media: management
and surveillance in an era of pneumococcal resistance – a report from the
Drug-resistant Streptococcus pneumoniae Therapeutic Working Group.
Pediatr Infect Dis J 1999;18:1-9.
22. Heikkinen T, Thint M, Chonmaitree T. Prevalence of various respiratory
viruses in the middle ear during acute otitis media. N Engl J Med 1999;340:260-64.
23. Block SL. Causative pathogens, antibiotic resistance and therapeutic
considerations in acute otitis media. Pediatr Infect Dis J 1997;16:449-56.
24. Bluestone CD, Stephenson JS, Martin LM. Ten-year review of otitis
media pathogens. Pediatr Infect Dis J 1992;11:S7-11.
25. Andrade MA, Hoberman A, Glustein J et coll. Acute otitis media in
children with bronchiolitis. Pediatrics 1998;101:617-19.
26. Teele DW, Klein JO, Rosner B. Epidemiology of otitis media during
the first seven years of life in children in greater Boston: a prospective,
cohort study. J Infect Dis 1989;160:83-94.
27. Wang EE, Einarson TR, Kellner JD et coll. Antibiotic prescribing
for Canadian preschool children: evidence of overprescribing for viral respiratory
infections. Clin Infect Dis 1999;29:155-60.
28. Lieu TA, Ray GT, Black SB et coll. Projected cost-effectiveness of
pneumococcal conjugate vaccination of healthy infants and young children.
JAMA 2000;283:1460-8.
29. Pastor P, Medley F, Murphy TV. Invasive pneumococcal disease in Dallas
County, Texas: results from population-based surveillance in 1995. Clin
Infect Dis 1998;26:590-95.
30. Overturf GD, Powars D, Baraff LJ. Bacterial meningitis and septicemia
in sickle cell disease. Am J Dis Child 1977;131:784-87.
31. Overturf GD. Infections and immunizations of children with sickle
cell disease. Adv Pediatr Infect Dis 1999;14:191-218.
32. Wong WY, Overturf GD, Powars DR. Infection caused by Streptococcus
pneumoniae in children with sickle cell disease: epidemiology, immunologic
mechanisms, prophylaxis, and vaccination. Clin Infect Dis 1992;14:1124-36.
33. Topley JM, Cupidore L, Vaidya S et coll. Pneumococcal and other infections
in children with sickle-cell hemoglobin C (SC) disease. J Pediatr 1982;101:176-79.
34. Lane PA, Rogers ZR, Woods GM et coll. Fatal pneumococcal septicemia
in hemoglobin SC disease. J Pediatr 1994;124:859-62.
35. Bjornson AB, Falletta JM, Verter JI et coll. Serotype-specific immunoglobulin
G antibody responses to pneumococcal polysaccharide vaccine in children with
sickle cell anemia: effects of continued penicillin prophylaxis. J Pediatr
1996;129:828-35.
36. Fiore AE, Levine OS, Elliott JA et coll. Effectiveness of pneumococcal
polysaccharide vaccine for preschool-age children with chronic disease.
Emerg Infect Dis 1999;5:828-31.
37. Frankel RE, Virata M, Hardalo C et coll. Invasive pneumococcal disease:
clinical features, serotypes, and antimicrobial resistance patterns in cases
involving patients with and without human immunodeficiency virus infection.
Clin Infect Dis 1996;23:577-84.
38. Moore D, Nelson M, Henderson D. Pneumococcal vaccination and HIV
infection. Int J STD AIDS 1998;9:1-7.
39. Nuorti JP, Butler JC, Gelling L et coll. Epidemiologic relation between
HIV and invasive pneumococcal disease in San Francisco County, California.
Ann Intern Med 2000;132:182-90.
40. Farley JJ, King JC, Jr., Nair P et coll. Invasive pneumococcal disease
among infected and uninfected children of mothers with human immunodeficiency
virus infection. J Pediatr 1994;124:853-58.
41. Andiman WA, Mezger J, Shapiro E. Invasive bacterial infections in
children born to women infected with human immunodeficiency virus type 1.
J Pediatr 1994;124:846-52.
42. Mao C, Harper M, McIntosh K et coll. Invasive pneumococcal infections
in human immunodeficiency virus-infected children. J Infect Dis 1996;173:870-76.
43. Levine OS, Farley M, Harrison LH et coll. Risk factors for invasive
pneumococcal disease in children: a population-based case-control study in
North America. Pediatrics 1999;103:E28.
44. Gessner BD, Ussery XT, Parkinson AJ et coll. Risk factors for invasive
disease caused by Streptococcus pneumoniae among Alaska native children
younger than two years of age. Pediatr Infect Dis J 1995;14:123-28.
45. Takala AK, Jero J, Kela E et coll. Risk factors for primary invasive
pneumococcal disease among children in Finland. JAMA 1995;273:859-64.
46. Uhari M, Mantysaari K, Niemela M. A meta-analytic review of the risk
factors for acute otitis media. Clin Infect Dis 1996;22:1079-83.
47. Nafstad P, Hagen JA, Oie L et coll. Day care centers and respiratory
health. Pediatrics 1999;103:753-58.
48. Paradise JL, Rockette HE, Colborn DK et coll. Otitis media in 2253
Pittsburgh-area infants: prevalence and risk factors during the first two
years of life. Pediatrics 1997;99:318-33.
49. National Centre for Streptococcus - Annual Reports. URL : <http://bugs.uah.ualberta.ca/vlab/ncs/ncs.htm>.
Date d’accès : sept. 2001.
50. Lovgren M, Spika JS, Talbot JA. Invasive Streptococcus pneumoniae
infections: serotype distribution and antimicrobial resistance in Canada,
1992-1995. CMAJ 1998;158:327-31.
51. Butler JC, Breiman RF, Lipman HB et coll. Serotype distribution of
Streptococcus pneumoniae infections among preschool children in the
United States, 1978-1994: implications for development of a conjugate vaccine.
J Infect Dis 1995;171:885-89.
52. Finland M, Barnes MW. Changes in occurrence of capsular serotypes
of Streptococcus pneumoniae at Boston City Hospital during selected
years between 1935 and 1974. J Clin Microbiol 1977;5:154-66.
53. Yu X, Gray B, Chang S et coll. Immunity to cross-reactive serotypes
induced by pneumococcal conjugate vaccines in infants. J Infect Dis 1999;180:1569-76.
54. Block SL, Hedrick JA, Harrison CJ. Pneumococcal serotypes from acute
otitis media in rural Kentucky. 39e Interscience Conference
on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, (Californie)
: Sept 26-29, 1999. Abstrait no 1185, 1999;677.
55. Eskola J, Kilpi T, Palmu A et coll. Efficacy of a pneumococcal conjugate
vaccine against acute otitis media. N Engl J Med 2001;344:403-9.
56. Canadian Bacterial Surveillance Network. National and provincial
data on Streptococcus pneumoniae. URL : <http://microbiology.mtsinai.on.ca/research/cbsn.html>.
Date d’accès : sept. 2001.
57. Scheifele D, Halperin S, Pelletier L et coll. Reduced susceptibility
to penicillin among pneumococci causing invasive infection in children - Canada,
1991 to 1998. Can J Infect Dis 2001;12:241-46.
58. Block SL, Harrison CJ, Hedrick JA et coll. Penicillin-resistant Streptococcus
pneumoniae in acute otitis media: risk factors, susceptibility patterns
and antimicrobial management. Pediatr Infect Dis J 1995;14:751-59.
59. Hofmann J, Cetron MS, Farley MM et coll. The prevalence of drug-resistant
Streptococcus pneumoniae in Atlanta. N Engl J Med 1995;333:481-86.
60. Arnold KE, Leggiadro RJ, Breiman RF et coll. Risk factors for carriage
of drug-resistant Streptococcus pneumoniae among children in Memphis,
Tennessee. J Pediatr 1996;128:757-64.
61. Reichler MR, Allphin AA, Breiman RF et coll. The spread of multiply
resistant Streptococcus pneumoniae at a day care center in Ohio.
J Infect Dis 1992;166:1346-53.
62. Dagan R, Melamed R, Muallem M et coll. Nasopharyngeal colonization
in southern Israel with antibiotic-resistant pneumococci during the first
2 years of life: relation to serotypes likely to be included in pneumococcal
conjugate vaccines. J Infect Dis 1996;174:1352-55.
63. Catalan MJ, Fernandez JM, Vazquez A et coll. Failure of cefotaxime
in the treatment of meningitis due to relatively resistant Streptococcus
pneumoniae. Clin Infect Dis 1994;18:766-69.
64. Sloas MM, Barrett FF, Chesney PJ et coll. Cephalosporin treatment
failure in penicillin- and cephalosporin-resistant Streptococcus pneumoniae
meningitis. Pediatr Infect Dis J 1992;11:662-66.
65. Tan TQ, Mason EO, Jr., Barson WJ et coll. Clinical characteristics
and outcome of children with pneumonia attributable to penicillin-susceptible
and penicillin-nonsusceptible Streptococcus pneumoniae. Pediatrics
1998;102:1369-75.
66. Friedland IR. Comparison of the response to antimicrobial therapy
of penicillin-resistant and penicillin-susceptible pneumococcal disease.
Pediatr Infect Dis J 1995;14:885-90.
67. Feikin DR, Schuchat A, Kolczak M et coll. Mortality from invasive
pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997.
Am J Public Health 2000;90:223-29.
68. Comité consultatif national de l’immunisation. Guide canadien
d’immunisation. 5e éd. Ottawa (Ontario) : Santé
Canada, 1998. (No de cat. H49-8/1998F.)
69. Leinonen M, Sakkinen A, Kalliokoski R et coll. Antibody response
to 14-valent pneumococcal capsular polysaccharide vaccine in pre-school age
children. Pediatr Infect Dis 1986;5:39-44.
70. Ekdahl K, Braconier JH, Svanborg C. Impaired antibody response to
pneumococcal capsular polysaccharides and phosphorylcholine in adult patients
with a history of bacteremic pneumococcal infection. Clin Infect Dis 1997;25:654-60.
71. Nielsen H, Kvinesdal B, Benfield TL et coll. Rapid loss of specific
antibodies after pneumococcal vaccination in patients with human immunodeficiency
virus-1 infection. Scand J Infect Dis 1998;30:597-601.
72. Broome CV, Facklam RR, Fraser DW. Pneumococcal disease after pneumococcal
vaccination: an alternative method to estimate the efficacy of pneumococcal
vaccine. N Engl J Med 1980;303:549-52.
73. O’Brien KL, Steinhoff MC, Edwards K et coll. Immunologic priming
of young children by pneumococcal glycoprotein conjugate, but not polysaccharide,
vaccines. Pediatr Infect Dis J 1996;15:425-30.
74. Obaro SK, Huo Z, Banya WA et coll. A glycoprotein pneumococcal conjugate
vaccine primes for antibody responses to a pneumococcal polysaccharide vaccine
in Gambian children. Pediatr Infect Dis J 1997;16:1135-40.
75. Rennels MB, Edwards KM, Keyserling HL et coll. Safety and immunogenicity
of heptavalent pneumococcal vaccine conjugated to CRM197 in United States
infants. Pediatrics 1998;101:604-11.
76. Shinefield HR, Black S, Ray P et coll. Safety and immunogenicity
of heptavalent pneumococcal CRM197 conjugate vaccine in infants and toddlers.
Pediatr Infect Dis J 1999;18:757-63.
77. Obaro SK, Adegbola RA, Chang I et coll. Safety and immunogenicity
of a nonavalent pneumococcal vaccine conjugated to CRM197 administered simultaneously
but in a separate syringe with diphtheria, tetanus and pertussis vaccines
in Gambian infants. Pediatr Infect Dis J 2000;19:463-69.
78. Kayhty H, Ahman H, Ronnberg PR et coll. Pneumococcal polysaccharide-meningococcal
outer membrane protein complex conjugate vaccine is immunogenic in infants
and children. J Infect Dis 1995;172:1273-78.
79. Blum MD, Dagan R, Mendelman PM et coll. A comparison of multiple
regimens of pneumococcal polysaccharide-meningococcal outer membrane protein
complex conjugate vaccine and pneumococcal polysaccharide vaccine in toddlers.
Vaccine 2000;18:2359-67.
80. Dagan R, Melamed R, Zamir O et coll. Safety and immunogenicity of
tetravalent pneumococcal vaccines containing 6B, 14, 19F and 23F polysaccharides
conjugated to either tetanus toxoid or diphtheria toxoid in young infants
and their boosterability by native polysaccharide antigens. Pediatr Infect
Dis J 1997;16:1053-59.
81. Anderson EL, Kennedy DJ, Geldmacher KM et coll. Immunogenicity of
heptavalent pneumococcal conjugate vaccine in infants. J Pediatr 1996;128:649-53.
82. Wuorimaa T, Dagan R, Eskola J et coll. Tolerability and immunogenicity
of an eleven-valent pneumococcal conjugate vaccine in healthy toddlers.
Pediatr Infect Dis J 2001;20:272-77.
83. Anttila M, Eskola J, Ahman H et coll. Avidity of IgG for Streptococcus
pneumoniae type 6B and 23F polysaccharides in infants primed with pneumococcal
conjugates and boosted with polysaccharide or conjugate vaccines. J Infect
Dis 1998;177:1614-21.
84. Ahman H, Kayhty H, Tamminen P et coll. Pentavalent pneumococcal oligosaccharide
conjugate vaccine PncCRM is well-tolerated and able to induce an antibody
response in infants. Pediatr Infect Dis J 1996;15:134-39.
85. Black S, Shinefield H, Fireman B et coll. Efficacy, safety and immunogenicity
of heptavalent pneumococcal conjugate vaccine in children. Northern California
Kaiser Permanente Vaccine Study Center Group. Pediatr Infect Dis J 2000;19:187-95.
86. Vernacchio L, Neufeld EJ, MacDonald K et coll. Combined schedule
of
7-valent pneumococcal conjugate vaccine followed by 23-valent pneumococcal
vaccine in children and young adults with sickle cell disease. J Pediatr
1998;133:275-78.
87. O’Brien KL, Winkelstein JA, Santosham M et coll. Immunogenicity of
a pneumococcal protein conjugate vaccine in infants with sickle cell disease.
Pediatr Res 1996;39:160.
88. Nowak-Wegrzyn AH, Winkelstein JA, Stover BM et coll. Serum opsonic
activity for Streptococcus pneumoniae types 6B and 14 in infants with
sickle cell disease after immunization with pneumococcal protein conjugate
vaccine. In: Pediatric Academic Societies Conference. San Fransisco: 1999.
89. Goldblatt D, Akoto AY, AsafoAdjei E et coll. Immunogenicity and the
generation of immune memory following 9-valent pneumococcal conjugate vaccination
in Ghanaian infants with sickle cell disease. In: Program and Abstracts
of the 40th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy.
Toronto, Ont.: American Society for Microbiology, 2000: Presentation 688.
90. King JC, Jr., Vink PE, Farley JJ et coll. Comparison of the safety
and immunogenicity of a pneumococcal conjugate with a licensed polysaccharide
vaccine in human immunodeficiency virus and non-human immunodeficiency virus-infected
children. Pediatr Infect Dis J 1996;15:192-96.
91. King JC, Jr., Vink PE, Farley JJ et coll. Safety and immunogenicity
of three doses of a five-valent pneumococcal conjugate vaccine in children
younger than two years with and without human immunodeficiency virus infection.
Pediatrics 1997;99:575-80.
92. Vernacchio L, Romero-Steiner S, Martinez JE et coll. Comparison of
an opsonophagocytic assay and IgG ELISA to assess responses to pneumococcal
polysaccharide and pneumococcal conjugate vaccines in children and young adults
with sickle cell disease. J Infect Dis 2000;181:1162-66.
93. Sanders LA, Rijkers GT, Tenbergen-Meekes AM et coll. Immunoglobulin
isotype-specific antibody responses to pneumococcal polysaccharide vaccine
in patients with recurrent bacterial respiratory tract infections. Pediatr
Res 1995;37:812-19.
94. Freijd A, Hammarstrom L, Persson MA et coll. Plasma anti-pneumococcal
antibody activity of the IgG class and subclasses in otitis prone children.
Clin Exp Immunol 1984;56:233-38.
95. Epstein MM, Gruskay F. Selective deficiency in pneumococcal antibody
response in children with recurrent infections. Ann Allergy Asthma Immunol
1995;75:125-31.
96. Sorensen RU, Leiva LE, Giangrosso PA et coll. Response to a heptavalent
conjugate Streptococcus pneumoniae vaccine in children with recurrent
infections who are unresponsive to the polysaccharide vaccine. Pediatr
Infect Dis J 1998;17:685-91.
97. Breukels MA, Rijkers GT, Voorhorst-Ogink MM et coll. Pneumococcal
conjugate vaccine primes for polysaccharide-inducible IgG2 antibody response
in children with recurrent otitis media acuta. J Infect Dis 1999;179:1152-56.
98. Barnett ED, Pelton SI, Cabral HJ et coll. Immune response to pneumococcal
conjugate and polysaccharide vaccines in otitis-prone and otitis-free children.
Clin Infect Dis 1999;29:191-92.
99. Miernyk KM, Parkinson AJ, Rudolph KM et coll. Immunogenicity of a
heptavalent pneumococcal conjugate vaccine in Apache and Navajo Indian, Alaska
native, and non-native American children aged < 2 years. Clin
Infect Dis 2000;31:34-41.
100. Moulton LH, O’Brien KL, Kohberger R et coll. Design of a group-randomized
Streptococcus pneumoniae vaccine trial. Control Clin Trials 2001;22:438-52.
101. Jonsdottir I, Ingolfsdottir G, Saeland E et coll. A single dose
of pneumococcal conjugate vaccine elicits functional antibodies and induces
memory in toddlers. In: Program and Abstracts of the 40th Annual Interscience
Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ont.: American
Society for Microbiology, 2000. Presentation No. 43.
102. Dagan R, Melamed R, Muallem M et coll. Reduction of nasopharyngeal
carriage of pneumococci during the second year of life by a heptavalent conjugate
pneumococcal vaccine. J Infect Dis 1996;174:1271-78.
103. Dagan R, Fraser D, Sikuler-Cohen M et coll. Reduction of nasopharyngeal
(np) carriage in day care center (dcc) attendees after vaccination with a
9 valent crm197 conjugate pneumococcal vaccine (pnccrm9) protection against
individual serotypes. In: Program and Abstracts of the 40th Annual
Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto,
Ontario: American Society for Microbiology, 2000. Presentation No. 686.
104. Kristinsson KG, Sigurdardottir ST, Gudnason T. Effect of vaccination
with octavalent protein conjugated pneumococcal vaccines on pneumococcal carriage
in infants. In: Program and Abstracts of the 37th Annual Interscience
Conference on Antimicrobial Agents and Chemotherapy. Toronto, Ont.: American
Society for Microbiology, 1997:193.
105. Dagan R, Muallem M, Melamed R et coll. Reduction of pneumococcal
nasopharyngeal carriage in early infancy after immunization with tetravalent
pneumococcal vaccines conjugated to either tetanus toxoid or diphtheria toxoid.
Pediatr Infect Dis J 1997;16:1060-64.
106. Mbelle N, Huebner RE, Wasas AD et coll. Immunogenicity and impact
on nasopharyngeal carriage of a nonavalent pneumococcal conjugate vaccine.
J Infect Dis 1999;180:1171-76.
107. Dagan R, Givon-Lavi N, Porat N et coll. Immunization of toddlers
attending day care centers with a 9-valent conjugate pneumococcal vaccine
reduces transmission of Streptococcus pneumoniae and antibiotic resistant
S. pneumoniae to their young siblings. In: Program and
Abstracts of the 40th Annual Interscience Conference on Antimicrobial
Agents and Chemotherapy. Toronto, Ont.: American Society for Microbiology,
2000. Presentation No. 687.
108. Gaston MH, Verter JI, Woods G et coll. Prophylaxis with oral penicillin
in children with sickle cell anemia. A randomized trial. N Engl J Med
1986;314:1593-99.
109. Infectious Diseases and Immunization Committee CPS. Prevention and
therapy of bacterial infections for children with asplenia or hyposplenia.
Paediatrics and Child Health 1999;4:417-21.
110. Powers DC, Anderson EL, Lottenbach K et coll. Reactogenicity and
immunogenicity of a protein-conjugated pneumococcal oligosaccharide vaccine
in older adults. J Infect Dis 1996;173:1014-18.
111. Ahmed F, Steinhoff MC, Rodriguez-Barradas MC et coll. Effect of
human
immunodeficiency virus type 1 infection on the antibody response to a
glycoprotein conjugate pneumococcal vaccine: results from a randomized
trial. J Infect Dis 1996;173:83-90.
112. The Canadian Task Force on the Periodic Health Examination. The
Canadian
guide to clinical preventive health care. 1994 update ed. Ottawa, Ont.:
Minister of Supply and Services Canada, 1994. (Cat. No. H21-117/
1994E.)
[Précédente]
[Relevé des maladies
transmissibles au Canada]
|
